Shares in Novocure (NSDQ:NVCR) jumped nearly 50% today after the company touted 5-year data today from the Phase III pivotal EF-14 trial evaluating its Optune device with temozolomide chemotherapy for the treatment of newly-diagnosed glioblastoma.
Data from 695 patients show a consistent and maintained improvement in overall survival at 2, 3, 4 and 5 years, the St. Helier, N.J.-based company said. Novocure’s Optune mobile device delivers low-intensity, intermediate frequency, alternating electric fields, called “tumor treating fields” or TTFields, to inhibit cancer cell replication
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure touts long-term data for Optune, chemo combination therapy for glioblastoma appeared first on MassDevice.
from MassDevice http://ift.tt/2nwwB0j
Cap comentari:
Publica un comentari a l'entrada